New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2013
19:03 EDTSYNSynthetic Biologics reiterates collaboration with Intrexon still in effect
Synthetic Biologics reiterated that the exclusive channel collaboration agreement dated August 6, 2012 between the company and Intrexon remains in effect. This agreement governs a "channel collaboration" arrangement for the use of Intrexon's technology relating to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases.
News For SYN From The Last 14 Days
Check below for free stories on SYN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 12, 2014
13:30 EDTSYNSynthetic Biologics confirms receipt of orphan drug designation for SYN-005
Subscribe for More Information
10:03 EDTSYNSynthetic Biologics treatment of Bordetella pertussis granted orphan status
Reference Link
07:00 EDTSYNSynthetic Biologics to host investor day
Investor Day to be held on September 16 at 9 am. Webcast Link
September 11, 2014
07:49 EDTSYNSynthetic Biologics to host conference call
Subscribe for More Information
September 10, 2014
07:09 EDTSYNAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
September 7, 2014
17:11 EDTSYNSynthetic Biologics highlights new data from C. difficile program
Synthetic Biologics announced preclinical data that further validate the company's novel approach to preventing Clostridium difficile,C. difficile. The U.S. Centers for Disease Control has identified C. difficile as an "urgent public health threat," and it has surpassed MRSA as the number one hospital-acquired infection in the United States. The data were highlighted on September 6 at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, in Washington, D.C.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use